Ahmed Gaballa

Ahmed Gaballa

Auto-generated profile, based on publicly available information

Ahmed Gaballa

Department of Epileptology, Krankenhaus Mara, Bethel Epilepsy Center Bielefeld University Bielefeld Germany

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 May 2026 in Epilepsia
Verified
Journal Article
Open access
ECErica Cecchini
Erica Cecchini
THTill Hartlieb
Till Hartlieb
AGAhmed Gaballa
Ahmed Gaballa
KKKatja Kobow
Katja Kobow
MKMitali Katoch
Mitali Katoch
LHLucas Hoffmann
Lucas Hoffmann
Objective: Mild malformation of cortical development with oligodendroglial hyperplasia in epilepsy (MOGHE) is an underrecognized pediatric cortical lesion associated with somatic X‐linked SLC35A2 variants in approximately 50% of individuals. The genetic etiology in individuals without detectable SLC35A2 mutations remains undefined, which limits our understanding of its pathomechanism and clinical characterization. The aim is to identify genetic correlates of MOGHE in individuals lacking pathogenic SLC35A2 variants and to investigate the clinicopathological and genomic correlations. Methods: We investigated archival brain tissue of 29 individuals (19 males, 10 females) with histopathologically confirmed MOGHE. Twenty individuals carried SLC35A2 variants, and nine individuals lacked detectable mutations in SLC35A2 or other epilepsy‐related genes. Brain tissue samples were analyzed using DNA methylation‐derived copy number variation (CNV) analysis, polymerase chain reaction (PCR), and chromogenic/fluorescent in situ hybridization (ISH). Results: CNV analysis identified Y‐chromosomal material in five of 10 females (50%) and mosaic Y‐chromosome gains in 16 of 19 males (84%), confirmed by PCR and ISH, and associated with lesional tissue. Exploratory stratification of the cohort by SLC35A2 status and Y‐chromosome gain revealed a tendency toward earlier seizure onset, multilobar involvement, and cognitive impairment in patients carrying both SLC35A2 mutations and Y‐chromosome gain; however, these differences did not reach statistical significance in our small cohort. Significance: The combined presence of Y‐chromosomal material in females, mosaic Y‐chromosome gains in males, and SLC35A2 variants represents a recurrent genomic feature in patients with MOGHE. These findings suggest that sex‐chromosome anomalies may contribute to the pathobiology of this epilepsy‐associated cortical malformation, highlighting the need to clarify the underlying molecular mechanisms of this clinicohistopathologic entity. Although the root cause, biological consequence, and clinical significance of brain somatic Y‐chromosomal gain remain to be further clarified, our findings identify a previously unrecognized genomic feature of MOGHE and provide a rationale for future research in MOGHE cohorts.

13 May 2025 in Epileptic Disorders
Verified
Journal Article
Open access
AGAhmed Gaballa
Ahmed Gaballa
CBChristian G. Bien
Christian G. Bien
PGPhilip Grewe
Philip Grewe
AHAnne Hagemann
Anne Hagemann
TKThilo Kalbhenn
Thilo Kalbhenn
TCThomas Cloppenborg
Thomas Cloppenborg
Objective: (1) To compare use, benefits, and complications of stereo‐EEG (SEEG) and subdural EEG (SD) in presurgical epilepsy candidates. (2) To evaluate the effectiveness of both methods in delineation of the epileptogenic zone (EZ) and guiding tailored resective surgery.Methods: We included patients with SEEG or SD evaluations in children and adults at the Bethel Epilepsy Centre, Germany, between 2000 and 2020. We retrospectively assessed epilepsy related parameters, main indication of iEEG (intracranial EEG, for identification of the EZ and functional mapping), complications, seizure, and functional outcome. The second objective was addressed by a subgroup analysis in patients with focal cortical dysplasia (FCD) and mild malformation of cortical development with oligodendroglial hyperplasia (MOGHE) for delineation of the EZ.Results: Two hundred and nineteen iEEG explorations in 215 patients (age range: 1.3–64.6 years) were assessed (SEEG, n = 78; SD, n = 141). We observed a change in iEEG usage away from SD towards SEEG. In the SEEG group, the decision rate against surgery was higher (SEEG: 23.1% vs. SE: 3.5%, p < .001) and more patients achieved seizure freedom 2 years after surgery (SEEG: 67.8% vs. SD: 46.5%, p = .008). For all iEEG, complications were rare; symptomatic intracranial bleeding only occurred in the SD group (n = 6, 4.3%). In patients with FCD/MOGHE for delineation of the EZ, all patients were operated with favorable seizure freedom after SEEG, but with acceptance of planned neurological deficits (SEEG n = 8, SD n = 20, seizure freedom rate SEEG 87.5% vs. SD 30%, p = .011; neurological deficits: SEEG n = 3 planned motor deficits vs. SD n = 1 unplanned motor deficit due to ischemia).Significance: SEEG has largely replaced SD in iEEG for the identification of the EZ. It is better tolerated and allows more freedom of choice with respect to resective surgery, resulting in the better identification of surgical candidates and delineation of the EZ with favorable seizure outcomes.

8 June 2026 in medRxiv
Verified
Preprint
Open access
PDF file
VGVadym Gnatkovsky
Vadym Gnatkovsky
EPEkaterina Poguzhelskaya
Ekaterina Poguzhelskaya
VBValeri Borger
Valeri Borger
RSRainer Surges
Rainer Surges
KKKerstin Alexandra Klotz
Kerstin Alexandra Klotz
KKKatja Kobow
Katja Kobow
Mild malformation of cortical development with oligodendroglial hyperplasia and epilepsy (MOGHE) is a recently recognized cause of drug-resistant focal epilepsy. It is often MRI-negative or shows imaging features mimicking focal cortical dysplasias, which makes recognition difficult and limits presurgical counseling. We aimed to identify an intracranial EEG (iEEG) biomarker that distinguishes MOGHE from other developmental brain lesions encountered in epilepsy surgery. In a retrospective multicenter test cohort of 38 patients (18 MOGHE, 20 non-MOGHE), we analyzed long-term stereo-EEG and subdural recordings. Only MOGHE patients showed highly stereotyped clusters of very brief low-voltage fast activity (LVFA) events, organized into status-like 3 to 12-minute episodes that often lacked clear clinical symptoms. LVFA clusters were present in 16/18 MOGHE and 0/22 non-MOGHE patients. We then tested diagnostic performance in an independent, blinded single-center validation cohort of 22 patients (11 MOGHE, 11 non-MOGHE), in which visual identification of LVFA clusters correctly classified 10/11 MOGHE and 10/11 non-MOGHE cases (Cohen’s κ=0.82). Penalized logistic regression further confirmed MOGHE histology as the strongest predictor of LVFA clusters, independent of age and lobe localization. Because LVFA clusters can be recognized visually on routine intracranial EEG recordings without specialized software, this biomarker is readily applicable in clinical practice and may improve presurgical identification of MOGHE. Future prospective studies should determine whether its recognition influences surgical planning, improves outcome prediction, or facilitates selection of patients for mechanism-based therapies. Highlights: Clusters of brief LVFA in intracranial EEG are a lesion-specific biomarker of MOGHE compared to mMCD and FCD2 LVFA clusters reliably distinguished MOGHE from non-MOGHE lesions (mMCD and FCD2) in both a multicenter test cohort and an independent blinded validation cohort. Younger age at seizure onset is a secondary independent modifier, while frontal localization and age at intracranial recording are not. Clinicians can detect LVFA clusters on continuous intracranial EEG using routine montages and ≥60-second review windows, without any specialized software. LVFA clusters show a characteristic temporal organization and burden in MOGHE, indicating a distinct pattern of pathological network activity in this lesion type.

13 October 2026 in Epileptic Disorders
Verified
Journal Article
Closed access
PDF file
AGAhmed Gaballa
Ahmed Gaballa

6 September 2026 in Epilepsy & Behavior
Verified
Journal Article
Open access
AHAnne Hagemann
Anne Hagemann
AGAhmed Gaballa
Ahmed Gaballa
CBChristian G. Bien
Christian G. Bien
RTRupprecht Thorbecke
Rupprecht Thorbecke
BMBirgitt Müffelmann
Birgitt Müffelmann

20 May 2026 in Epilepsy & Behavior
Verified
Journal Article
Open access
AGAhmed Gaballa
Ahmed Gaballa
GBGalal Banat
Galal Banat
AHAnne Hagemann
Anne Hagemann
CBChristian Brandt
Christian Brandt
The 20-item Anxiety, Abuse, and Somatization Questionnaire (AASQ) was developed by Trainor et al. (2020) to differentiate functional/dissociative seizures (FDS) from epilepsy. The objectives of our study were to validate the German version of the AASQ and to evaluate its diagnostic accuracy in distinguishing between FDS and epileptic seizures. We conducted a single-center prospective study from October 2023 to February 2025. Newly admitted patients with suspected epileptic seizures or FDS were included and completed the German version of the AASQ. The AASQ was distributed to 184 patients. Of these, 138 were successfully included. We classified the patients into four groups according to the final diagnosis as follows: (1) epilepsy (n = 88); (2) FDS (n = 21); (3) epilepsy and FDS (n = 9); and (4) other (patients with diagnoses other than epilepsy or FDS, n = 20). Patients in the FDS group had higher AASQ scores than patients in the epilepsy group (median number of endorsed items [range]; FDS: 8 [1-20], epilepsy: 4 [0-20]). At a threshold of > 2.4, the AASQ mean score showed a high negative predictive value (NPV = 88%, 95% confidence interval [CI]: 83-91%) and a high specificity for FDS (0.97, 95% CI: 0.90-0.99). With this threshold, we achieved a sensitivity of 0.43 and a positive predictive value of 75%. Including the number of anti-seizure medications in the prediction improved the sensitivity to 0.76. The German version of the AASQ serves as a concise screening instrument supporting the differential diagnosis between FDS and epileptic seizures. It shows only moderate sensitivity but high specificity and NPV and thus enables the exclusion of FDS in cases with low scores with high confidence.